Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H1 2018’, provides an overview of the Vasomotor Symptoms of Menopause (Hot Flashes) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vasomotor Symptoms of Menopause (Hot Flashes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vasomotor Symptoms of Menopause (Hot Flashes) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vasomotor Symptoms of Menopause (Hot Flashes)

- The report reviews pipeline therapeutics for Vasomotor Symptoms of Menopause (Hot Flashes) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Vasomotor Symptoms of Menopause (Hot Flashes) therapeutics and enlists all their major and minor projects

- The report assesses Vasomotor Symptoms of Menopause (Hot Flashes) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Vasomotor Symptoms of Menopause (Hot Flashes)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Vasomotor Symptoms of Menopause (Hot Flashes)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Vasomotor Symptoms of Menopause (Hot Flashes) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

EndoCeutics Inc

MenoGeniX Inc

Mithra Pharmaceuticals SA

Ogeda SA

Pherin Pharmaceuticals Inc

TherapeuticsMD Inc

EndoCeutics Inc

MenoGeniX Inc

Mithra Pharmaceuticals SA

Ogeda SA

Pherin Pharmaceuticals Inc

TherapeuticsMD Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Vasomotor Symptoms of Menopause (Hot Flashes) – Overview

Vasomotor Symptoms ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Vasomotor Symptoms of Menopause (Hot Flashes) – Overview

Vasomotor Symptoms of Menopause (Hot Flashes) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Vasomotor Symptoms of Menopause (Hot Flashes) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Vasomotor Symptoms of Menopause (Hot Flashes) – Companies Involved in Therapeutics Development

EndoCeutics Inc

MenoGeniX Inc

Mithra Pharmaceuticals SA

Ogeda SA

Pherin Pharmaceuticals Inc

TherapeuticsMD Inc

Vasomotor Symptoms of Menopause (Hot Flashes) – Drug Profiles

acolbifene hydrochloride + prasterone – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Estetrol – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fezolinetant – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-101 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HBN-2 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MNGX-100 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-814 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PH-80HF – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Q-122 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TX-001HR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TX-006HR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TX-008HR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vasomotor Symptoms of Menopause (Hot Flashes) – Dormant Projects

Vasomotor Symptoms of Menopause (Hot Flashes) – Discontinued Products

Vasomotor Symptoms of Menopause (Hot Flashes) – Product Development Milestones

Featured News & Press Releases

May 30, 2018: Mithra Announces Further Positive Phase IIb Donesta Efficacy and Safety Data

May 03, 2018: MenoGeniX Awarded NIH Grant to Fund Phase Ib/IIa Clinical Trial

Apr 19, 2018: Mithra Announces Positive Donesta Phase IIb Study Achieving Primary Objective and Confirming Promising Safety Profile

Apr 17, 2018: Clinical Trial Begins For Promising New Post-Menopausal Therapy Treating Vasomotor Symptoms

Mar 08, 2018: TherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for TX-001HR

Jan 25, 2018: Mithra Announces Last Subject Completes Donesta Phase II Study

Dec 28, 2017: New Menopause Therapy from Fervent Pharmaceuticals to Begin Clinical Trial

Dec 28, 2017: TherapeuticsMD Announces Submission of New Drug Application for TX-001HR

Oct 13, 2017: Mithra Announces Completion of Recruitment in Donesta Phase II Study

Oct 05, 2017: TherapeuticsMD Announces Multiple Presentations Related to TX-001HR at NAMS 2017

Sep 27, 2017: Kandy Therapeutics Launched To Focus On A Breakthrough New Product in Women's Health

Apr 03, 2017: TherapeuticsMD Presents Positive Phase 3 Data in Two Presentations for TX-001HR at ENDO 2017

Jan 04, 2017: Ogeda announces positive data from Phase IIa trial of fezolinetant (ESN364) in the treatment of menopausal hot flashes

Dec 20, 2016: Ogeda announces fezolinetant as INN and issuance of U.S. patent for ESN364

Dec 05, 2016: TherapeuticsMD Announces Positive Top-Line Results from Pivotal Phase 3 Replenish Trial in Postmenopausal Women with Moderate to Severe Vasomotor Symptoms (VMS) Treated with TX-001HR

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes), H1 2018

Number of Products under Development by Companies, H1 ...

List of Tables

Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Vasomotor Symptoms of Menopause (Hot Flashes) – Pipeline by EndoCeutics Inc, H1 2018

Vasomotor Symptoms of Menopause (Hot Flashes) – Pipeline by MenoGeniX Inc, H1 2018

Vasomotor Symptoms of Menopause (Hot Flashes) – Pipeline by Mithra Pharmaceuticals SA, H1 2018

Vasomotor Symptoms of Menopause (Hot Flashes) – Pipeline by Ogeda SA, H1 2018

Vasomotor Symptoms of Menopause (Hot Flashes) – Pipeline by Pherin Pharmaceuticals Inc, H1 2018

Vasomotor Symptoms of Menopause (Hot Flashes) – Pipeline by TherapeuticsMD Inc, H1 2018

Vasomotor Symptoms of Menopause (Hot Flashes) – Dormant Projects, H1 2018

Vasomotor Symptoms of Menopause (Hot Flashes) – Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes), H1 2018

Number of Products under Development by Companies, H1 ...

List of Figures

Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports